1. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (GOLD). Update 2013.
2. Шмелева Н.М., Шмелев Е.И. Современные аспекты мукоактивной терапии в пульмонологической практике. Терапевт. арх. 2013; 3: 107–9.
3. Моногарова Н.Е., Глухов А.В., Закомолдина Т.В. и др. Опыт использования комбинации ацетилцистеина и амброксола у пациентов с ХОЗЛ. Укр. пульмонологич. вестн. 2006; 4: 29–31.
4. Balsamo R, Lanata L, Egan CG. Mucoactive drugs. Eur Respir Rev 2010; 19 (116): 127–33.
5. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. Available from: http://www.goldcopd.org/
6. Decramer M, Rutten-van Molken M, Dekhuijzen PN et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial. Lancet 2005; 365 (9470): 1552–60.
7. Stav D, Raz M. Effect of N-acetylcysteine on air trapping in COPD: a randomized placebo-controlled study. Chest 2009; 136: 381–6.
8. Zheng JP, Kang J, Huang SG et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet 2008; 371 (9629): 2013–8.
9. Malerba M, Ponticiello A, Radaeli A et al. Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST Trial). Pulm Pharmacol Ther 2004; 17 (1): 27–34.
10. Chenot JF, Weber P, Friede T. Efficacy of Ambroxol lozenges for pharyngitis: a meta-analysis. BMC Fam Pract 2014; 15: 45.
11. Kido H, Okumura Y, Yamada H et al. Proteases essential for human influenza virus entry into cells and their inhibitors as potential therapeutic agents. Curr Pharm Des 2007; 13 (4): 405–14.
12. Yang B, Yao DF, Ohuchi M et al. Ambroxol suppresses influenza-virus proliferation in the mouse airway by increasing antiviral factor levels. Eur Respir J 2002; 19 (5): 952–8.
13. Aihara M, Dobashi K, Akiyama M et al. Effects of N-acetylcysteine and ambroxol on the production of IL-12 and IL-10 in human alveolar macrophages. Respiration 2000; 67 (6): 662–71.
14. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganism. Clin Microbiol Rev 2002; 15: 167–93.
15. Flemming HC, Wingender J. The biofilm matrix. Nat Rev Microbiol 2010; 8: 623–33.
16. Vu B, Chen M, Crawford RJ et al. Bacterial extracellular polysaccharides involved in biofilm formation. Molecules 2009; 14: 2535–54.
17. Pintucci JP, Corno S, Garotta M. Biofilms and infections of the upper respiratory tract. Eur Rev Med Pharmacol Sci 2010; 14: 683–90. Biofilm life cycle. Montana State University Center for Biofilm Engineering. Available at ULR: http://www.biofilm.montana.edu
18. Cataldi M, Sblendorio V, Leo A, Piazza O. Biofilm-dependent airway infections: a role for ambroxol? Pulm Pharmacol Ther 2014; 28 (2): 98–108.
19. Li F. Effects of ambroxol on alginate of mature P. aeruginosa biofilms. Curr Microbiol 2008; 57 (1): 1–7.
20. Heukelekian H, Heller A. Relation between Food Concentration and Surface for Bacterial Growth. J Bacteriol 1940; 40 (4): 547–58.
21. Mack WN, Mack JP, Ackerson AO. Microbial film development in a trickling filter. Microb Ecol 1975; 2 (3): 215–26.
22. Sauer K, Camper AK, Ehrlich GD et al. Pseudomonas aeruginosa displays multiple phenotypes during development as a biofilm. J Bacteriol 2002; 184 (4): 1140–54.
23. Stewart PS, Franklin MJ. Physiological hetero-geneity in biofilms. Nat Rev Microbiol 2008; 6 (3): 199–210.
24. Miller MB, Bassler BL. Quorum sensing in bacteria. Annu Rev Microbiol 2001; 55: 165–99.
25. Yung-Hua Li. Xiaolin Tian. Quorum Sensing and Bacterial Social Interactions in Biofilms Sensors 2012; 12: 2519–38.
26. Ceri H, Olson ME, Stremick C et al. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 1999; 37: 1771–6.
27. Desrosiers M, Bendauah Z, Barbeau J. Effectiveness of topical antibiotics on Staphylococcus aureus biofilm in vitro. Am J Rhinol 2007; 21: 149–53.
28. Lambiase A, Rossano F, Piazza O et al. Typing of Pseudomonas aeruginosa isolated from patients with VAP in an intensive care unit. New Microbiol 2009; 32: 277e83.
29. Adair CG, Gorman SP, Feron BM et al. Implications of endotracheal tube biofilm for ventilator-associated pneu- monia. Intensive Care Med 1999; 25: 1072e6.
30. Safdar N, Crnich CJ, Maki DG. The pathogenesis of ventilator-associated pneumonia: its relevance to developing effective strategies for prevention. Respir Care 2005; 50: 725e39.
31. Sethi S, Sethi R, Eschberger K et al. Airway bacterial concentrations and exacerbations of chronic obstructive pulmonarydisease. Am J Respir Crit Care Med 2007; 176: 356e61.
32. Eldika N, Sethi S. Role of nontypeable Haemophilus influenzae in exacerbations and progression of chronic obstructive pulmonary disease. Curr Opin Pulm Med 2006; 12: 118e24.
33. Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet 2011; 378: 1015e26.
34. Sethi S, Murphy TF. Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clin Microbiol Rev 2001; 14: 336e63.
35. Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacer- bations of chronic obstructive pulmonary disease. N Engl J Med 2002; 347: 465e71
36. Riise GC, Qvarfordt I, Larsson S et al. Inhibitory effect of N-acetylcysteine on adherence of Streptococcus pneumoniae and Haemophilus influenzae to human oropharyngeal epithelial cells in vitro. Respiration 2000; 67: 552e8.
37. Hafez MM, Aboulwafa MM, Yassien MA, Hassouna NA. Activity of some mucolytics against bacterial adherence to mammalian cells. Appl Biochem Biotechnol 2009; 158: 97e112.
38. Yang H. Effect of ambroxol on permeability of ciprofloxacin across Pseudomonas aeruginosa biofilm. Chin J Antibiot 2007; 32 (4): 221–4.
39. Lu Q, Yu J, Bao L et al. Effects of combined treatment with ambroxol and ciprofloxacin on catheter-associated Pseudomonas aeruginosa biofilms in a rat model. Chemotherapy 2013; 59 (1): 51–6; doi: 10.1159/000351107
40. Bonnetti P. Ambroxol plus amoxicillin versus amoxicillin alone in various respiratory tract infections. Investig Med International 1993; 20: 99–103.
41. Neria JP, Rubi EG. Response to the combination of ambroxol/amoxicillin versus amoxicillin alone in patients with acute respiratory infection. Comparative study of antibiotic levels in bronchial mucus and plasma. Compend Invest Clin Lat Am 1992; 12 (1): 5–10.
42. Franchini F et al. Effect of a mucolytic agent on the bioavailability of antibiotics in patients with chronic respiratory disease. Curr Ther Res 1988; 43 (4): 734–42.
43. Spatola J et al. Influence of Ambroxol on lung tissue penetration of amoxicillin. Arznein Forsch Drug Res 1987; 37 [11] (8): 967–8.
44. http://www.medindia.net/doctors/drug_information/index.asp
45. Pfeifer S, Zissel G, Kienast K, Müller-Quernheim J. Reduction of cytokine release of blood and bronchoalveolar mononuclear cells by ambroxol. Eur J Med Res 1997; 2 (3): 129–32.
46. Zhang B, Liu Y. Prophylaxis against ventilator-induced lung injury by Ambroxol Zhonghua Yi Xue Za Zhi 2000; 80 (1): 51–3.
47. Zhao SP, Guo QL, Wang RK, Wang E. Oxidative and anti-oxidative effects of ambroxol on acute hydrochloric acid-induced lung injury in rats. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2004; 29 (5): 586–8.
48. Nowak D, Antczak A, Król M et al. Antioxidant properties of Ambroxol. Free Radic Biol Med 1994; 16 (4): 517–22.
49. Qiu XW, Wang JH, Li ZQ. Management of extensive burn accompanying severe inhalation injury. Di Yi Jun Yi Da Xue Xue Bao 2004; 24 (5): 597–9.

К.А.Зыков1, О.Ю.Агапова1, Е.И.Соколов2

1 Лаборатория пульмонологии НИМСИ ГБОУ ВПО МГМСУ им. А.И.Евдокимова Минздрава России;
2 Кафедра факультетской терапии и профессиональных болезней ГБОУ ВПО МГМСУ им. А.И.Евдокимова Минздрава России